These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
213 related articles for article (PubMed ID: 1971563)
1. Metabolic disposition studies on simvastatin, a cholesterol-lowering prodrug. Vickers S; Duncan CA; Chen IW; Rosegay A; Duggan DE Drug Metab Dispos; 1990; 18(2):138-45. PubMed ID: 1971563 [TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo biotransformation of simvastatin, an inhibitor of HMG CoA reductase. Vickers S; Duncan CA; Vyas KP; Kari PH; Arison B; Prakash SR; Ramjit HG; Pitzenberger SM; Stokker G; Duggan DE Drug Metab Dispos; 1990; 18(4):476-83. PubMed ID: 1976071 [TBL] [Abstract][Full Text] [Related]
3. Metabolic disposition of simvastatin in patients with T-tube drainage. Cheng H; Schwartz MS; Vickers S; Gilbert JD; Amin RD; Depuy B; Liu L; Rogers JD; Pond SM; Duncan CA Drug Metab Dispos; 1994; 22(1):139-42. PubMed ID: 8149872 [TBL] [Abstract][Full Text] [Related]
4. Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Aoki T; Nishimura H; Nakagawa S; Kojima J; Suzuki H; Tamaki T; Wada Y; Yokoo N; Sato F; Kimata H; Kitahara M; Toyoda K; Sakashita M; Saito Y Arzneimittelforschung; 1997 Aug; 47(8):904-9. PubMed ID: 9296275 [TBL] [Abstract][Full Text] [Related]
5. The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs. Davis HR; Pula KK; Alton KB; Burrier RE; Watkins RW Metabolism; 2001 Oct; 50(10):1234-41. PubMed ID: 11586500 [TBL] [Abstract][Full Text] [Related]
6. The physiological disposition of lovastatin. Duggan DE; Chen IW; Bayne WF; Halpin RA; Duncan CA; Schwartz MS; Stubbs RJ; Vickers S Drug Metab Dispos; 1989; 17(2):166-73. PubMed ID: 2565206 [TBL] [Abstract][Full Text] [Related]
7. Lovastatin and simvastatin--inhibitors of HMG CoA reductase and cholesterol biosynthesis. Alberts AW Cardiology; 1990; 77 Suppl 4():14-21. PubMed ID: 2073667 [TBL] [Abstract][Full Text] [Related]
8. In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s. Prueksaritanont T; Gorham LM; Ma B; Liu L; Yu X; Zhao JJ; Slaughter DE; Arison BH; Vyas KP Drug Metab Dispos; 1997 Oct; 25(10):1191-9. PubMed ID: 9321523 [TBL] [Abstract][Full Text] [Related]
10. Residual effects of lovastatin and simvastatin on urinary mevalonate excretions in patients with familial hypercholesterolemia. Pappu AS; Bacon SP; Illingworth DR J Lab Clin Med; 2003 Apr; 141(4):250-6. PubMed ID: 12677170 [TBL] [Abstract][Full Text] [Related]
11. Tissue-selective acute effects of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase on cholesterol biosynthesis in lens. Mosley ST; Kalinowski SS; Schafer BL; Tanaka RD J Lipid Res; 1989 Sep; 30(9):1411-20. PubMed ID: 2513368 [TBL] [Abstract][Full Text] [Related]
12. Regulation of early cholesterol biosynthesis in rat liver: effects of sterols, bile acids, lovastatin, and BM 15.766 on 3-hydroxy-3-methylglutaryl coenzyme A synthase and acetoacetyl coenzyme A thiolase activities. Honda A; Salen G; Nguyen LB; Xu G; Tint GS; Batta AK; Shefer S Hepatology; 1998 Jan; 27(1):154-9. PubMed ID: 9425931 [TBL] [Abstract][Full Text] [Related]
13. Biotransformation of lovastatin. V. Species differences in in vivo metabolite profiles of mouse, rat, dog, and human. Halpin RA; Ulm EH; Till AE; Kari PH; Vyas KP; Hunninghake DB; Duggan DE Drug Metab Dispos; 1993; 21(6):1003-11. PubMed ID: 7905377 [TBL] [Abstract][Full Text] [Related]
14. Transport mechanism of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors at the blood-brain barrier. Tsuji A; Saheki A; Tamai I; Terasaki T J Pharmacol Exp Ther; 1993 Dec; 267(3):1085-90. PubMed ID: 8263769 [TBL] [Abstract][Full Text] [Related]
16. Effects of simvastatin, a cholesterol synthesis inhibitor, on phosphatidylcholine synthesis in HepG2 cells. Yanagita T; Yamamoto K; Ishida S; Sonda K; Morito F; Saku K; Sakai T Clin Ther; 1994; 16(2):200-8. PubMed ID: 8062316 [TBL] [Abstract][Full Text] [Related]
17. beta-Oxidation of simvastatin in mouse liver preparations. Prueksaritanont T; Ma B; Fang X; Subramanian R; Yu J; Lin JH Drug Metab Dispos; 2001 Oct; 29(10):1251-5. PubMed ID: 11560866 [TBL] [Abstract][Full Text] [Related]
18. Determination of the HMG-CoA reductase inhibitors simvastatin, lovastatin, and pravastatin in plasma by gas chromatography/chemical ionization mass spectrometry. Morris MJ; Gilbert JD; Hsieh JY; Matuszewski BK; Ramjit HG; Bayne WF Biol Mass Spectrom; 1993 Jan; 22(1):1-8. PubMed ID: 8431499 [TBL] [Abstract][Full Text] [Related]
19. Brain cholesterol synthesis in mice is affected by high dose of simvastatin but not of pravastatin. Thelen KM; Rentsch KM; Gutteck U; Heverin M; Olin M; Andersson U; von Eckardstein A; Björkhem I; Lütjohann D J Pharmacol Exp Ther; 2006 Mar; 316(3):1146-52. PubMed ID: 16282522 [TBL] [Abstract][Full Text] [Related]
20. Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of losartan and its main metabolite EXP-3174 in rats: possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase inhibitors. Yang SH; Choi JS; Choi DH Pharmacology; 2011; 88(1-2):1-9. PubMed ID: 21709429 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]